Sparrow Acoustics Inc., dba Sparrow Bioacoustics Inc., closed a C$10 million (US$7.15 million) financing round to support continued adoption of its U.S. FDA-cleared Stethophone platform, which allows bioacoustics detection of structural and rhythmic heart anomalies directly through a smartphone. Sparrow is a Software as a Medical Device and the first medically cleared product that uses smartphones to capture and decipher cardiac sounds.

Who knew? In addition to adopting a new name, Kneu Health Ltd. recently raised $5.6 million in a seed funding round for its smart-phone-based platform which helps to monitor neurological disorders to enable timely intervention. The funds secured will be used to expand commercial operations in the U.S., scale deployments for Parkinson's disease and advance the monitoring capabilities of the platform for dementia.

Roche Holdings AG received CE-mark for the Kidney Klinrisk algorithm, an AI-based tool developed in collaboration with Klinrisk Inc. to stratify risk and assess the progressive decline in kidney function. The software will help clinicians to make more informed decisions when accessing adults with chronic kidney disease as well as individuals with diabetes or hypertension who are at elevated risk of kidney function decline.

With a new drug available to slow the progression of type 1 diabetes, Sanofi SA is partnering with two med-tech companies to increase screening for early-stage type 1 diabetes and identify eligible patients.

A month after raising $55 million to advance its AI-enhanced ultrasound diagnostics for cardiovascular disease, Ultromics Ltd. presented strong results for its U.S. FDA-cleared AI analysis of echocardiograms at the American Society of Echocardiography's 2025 Scientific Sessions in Nashville, Tenn. Ultromics' Echogo Amyloidosis was able to detect cardiac amyloidosis earlier and more accurately than traditional methods, missing fewer cases without increasing unnecessary testing.

In a real-world study, Eko Health Inc.’s AI-enabled digital stethoscope dramatically increased detection rates for atrial fibrillation, heart failure and valvular heart disease in primary care settings. Researchers from Imperial College London presented results from the study at the European Society of Cardiology in Madrid.

Researchers from the University of California, Davis (UC-Davis) continue to assemble intellectual property in support of their development of methods and techniques which improve the accuracy of wearable sensor technologies.

Signos Inc. landed U.S. FDA clearance for its over-the-counter glucose monitoring system, which combines Dexcom Inc.'s non-prescription Stelo continuous glucose monitor with an AI-powered platform focused on weight management and metabolism. The sensor transmits glucose readings to a smartphone app that interprets the data, provides guidance for healthy habits and educates the user.

A research team from Pusan National University has developed a novel deep learning model coined Moglo-Net, designed to enable three-dimensional reconstruction of images from hand-held ultrasound procedures.

Ultromics Ltd. raised $55 million in a series C financing round to expand its commercial footprint across the U.S. and invest in the development of new AI modules for earlier, more accurate detection of cardiovascular disease, Ross Upton, CEO and founder of Ultromics told BioWorld.